Table 1. Baseline characteristics of patients who initiated antiviral therapy.
| Characteristics | All Genotypes (n=15,849) | Genotype 1 (n=10,246) | Genotype 2 (n=3,686) | Genotype 3 (n=1,151) | Genotype 4 (n=47) | Genotype 5 (n=1) | Genotype 6 (n=457) | Untyped GTs (n=261) |
|---|---|---|---|---|---|---|---|---|
| Age, year | 62±13 | 64±13 | 61±13 | 50±10 | 58±11 | 48 | 60±13 | 54±13 |
| Male, n (%) | 7,866 (49.6) | 4,803 (46.9) | 1,696 (46.0) | 921 (80.0) | 28 (59.6) | 1 (100) | 244 (53.4) | 173 (66.3) |
| Ethnicity, n (%) (n=15,663) | ||||||||
| Asian | 14,263 (91.1) | 9,110 (89.5) | 3,602 (97.9) | 951 (83.3) | 16 (35.6) | – | 454 (99.3) | 130 (80.3) |
| White | 995 (6.4) | 763 (7.5) | 54 (1.5) | 150 (13.1) | 9 (20.0) | 0 | 19 (11.7) | |
| Black/African-American | 149 (1.0) | 125 (1.2) | 5 (0.1) | 3 (0.3) | 13 (28.9) | 0 | 3 (1.9) | |
| Hispanic/Latino | 197 (1.3) | 135 (1.3) | 16 (0.4) | 31 (2.7) | 6 (13.3) | 0 | 9 (5.6) | |
| American Indian/Alaska Native | 9 (0.1) | 8 (0.1) | 0 | 1 (0.1) | 0 | 0 | 0 | |
| Others | 50 (0.3) | 37 (0.4) | 2 (0.1) | 6 (0.5) | 1 (2.2) | 3 (0.7) | 1 (0.6) | |
| Treatment experienced, n (%) (n=15,725) | 3,922 (24.9) | 2,995 (29.5) | 691 (18.9) | 99 (8.6) | 13 (28.3) | 0 | 76 (16.7) | 48 (19.2) |
| Interferon regimens | 3,249 (20.7) | 2,455 (24.2) | 614 (16.8) | 65 (5.7) | 11 (23.9) | 0 | 67 (14.8) | 37 (14.8) |
| DAA regimens | 699 (4.3) | 537 (5.3) | 77 (2.1) | 34 (3.0) | 2 (4.4) | 0 | 8 (1.8) | 11 (4.4) |
| HBV co-infection, n (%) (n=11,835) | 353 (3.0) | 218 (2.9) | 73 (2.7) | 29 (2.7) | 1 (3.2) | – | 22 (5.7) | 10 (7.4) |
| HIV co-infection, n (%) (n=7,363) | 124 (1.7) | 32 (0.8) | 11 (0.7) | 49 (4.7) | 1 (3.9) | – | 6 (1.7) | 25 (12.6) |
| HCC, n (%) (n=15,811) | 1,352 (8.6) | 992 (9.7) | 242 (6.6) | 72 (6.3) | 2 (4.3) | – | 18 (3.9) | 26 (10.0) |
| HCC status, n (%) (n=1,312) | ||||||||
| Inactive | 1,031 (78.6) | 778 (80.2) | 176 (76.2) | 42 (60.0) | 2 (100) | – | 13 (72.2) | 20 (95.2) |
| Active | 281 (21.4) | 192 (19.8) | 55 (23.8) | 28 (40.0) | 0 | – | 5 (27.8) | 1 (4.8) |
| Cirrhosis, n (%) | 5,502 (34.8) | 3,748 (34.6) | 1,007 (27.3) | 468 (40.8) | 21 (44.7) | – | 156 (34.2) | 102 (39.2) |
| Cirrhosis stages, n (%) (n=3297) | ||||||||
| CTP A | 2,947 (89.4) | 2,091 (89.7) | 583 (92.7) | 202 (80.2) | 10 (90.9) | 38 (90.5) | 23 (69.7) | |
| CTP B | 299 (9.1) | 207 (8.9) | 41 (6.5) | 40 (15.9) | 1 (9.1) | 3 (7.1) | 7 (21.2) | |
| CTP C | 51 (1.6) | 32 (1.4) | 5 (0.8) | 10 (4.0) | 0 | 1 (2.4) | 3 (9.1) | |
| AST, IU/L | 45 (30–70) | 45 (31–69) | 41 (27–72) | 52 (35–80) | 34 (24–72) | 30 | 44 (29–72) | 45 (29–74) |
| ALT, IU/L | 43 (27–77) | 43 (27–72) | 40 (23–79) | 58 (34–96) | 40 (25–90) | 35 | 53 (29–90) | 66 (40–99) |
| Platelet count, ×103 U/L | 164±70 | 159±68 | 172±69 | 175±78 | 181±74 | – | 179±70 | 181±80 |
| Albumin, g/dL | 4.1±0.5 | 4.0±0.5 | 4.1±0.5 | 4.1±0.7 | 4.0±0.5 | – | 4.1±0.5 | 4.1±0.7 |
| Total bilirubin, mg/dL | 0.7 (0.6–1) | 0.7 (0.6–1) | 0.7 (0.5–1) | 0.8 (0.5–1.1) | 0.6 (0.4–0.8) | – | 0.7 (0.5–1) | 0.7 (0.5–1) |
| FIB–4 | 2.8 (1.7–4.9) | 3.1 (1.9–5.2) | 2.5 (1.5–4.4) | 2.0 (1.2–4.0) | 2.4 (1.2–3.3) | – | 2.0 (1.4–3.9) | 2.0 (1.1–3.7) |
| APRI | 0.7 (0.4–1.5) | 0.8 (0.4–1.5) | 0.6 (0.3–1.4) | 0.8 (0.5–1.6) | 0.6 (0.3–1.3) | – | 0.6 (0.4–1.3) | 0.6 (0.4–1.5) |
| Creatinine, mg/dL | 0.8 (0.6–0.9) | 0.8 (0.6–0.9) | 0.7 (0.6–0.9) | 0.9 (0.7–1.0) | 0.8 (0.6–1.0) | – | 0.8 (0.7–1.0) | 0.8 (0.6–1.0) |
| eGFR, mL/m/1.73 m2 | 88±22 | 86±22 | 89±23 | 93±20 | 95±23 | – | 85±23 | 92±26 |
| HCV RNA, log10 IU/mL | 6.0±0.8 | 6.0±0.8 | 5.9±1.0 | 6.0±0.9 | 5.8±0.8 | 6.9 | 6.3±0.9 | 6.1±0.9 |
| >800,000 IU/mL | 9,758 (63.2) | 6,438 (64.2) | 2,076 (57.5) | 745 (68.7) | 24 (53.3) | 1 (100) | 309 (72.0) | 165 (66.5) |
| Comorbidity, n (%) | – | |||||||
| Diabetes (n=14,674) | 2,772 (18.9) | 1,898 (20.1) | 660 (19.1) | 89 (8.4) | 10 (23.3) | 73 (17.0) | 42 (17.0) | |
| Hypertension (n=11,674) | 4,387 (37.6) | 2,991 (39.2) | 1,043 (37.1) | 125 (23.0) | 20 (51.3) | 146 (34.3) | 62 (27.9) | |
| Dyslipidemia (n=11,630) | 1,026 (8.8) | 656 (8.7) | 254 (8.9) | 45 (8.5) | 5 (13.2) | 49 (11.5) | 17 (7.8) | |
| Cardiovascular disease (n=9,491) | 636 (6.7) | 443 (7.3) | 146 (6.6) | 27 (5.1) | 1 (2.8) | 11 (2.6) | 8 (3.7) | |
| DAA treatment regimens | – | |||||||
| DCV/ASV | 2,357 (14.9) | 2,351 (23.0) | 5 (0.1) | 1 (0.1) | 0 | 0 | 0 | |
| PrOD±RBV | 1,603 (10.1) | 1,527 (14.9) | 75 (2.0) | 0 | 0 | 0 | 1 (0.4) | |
| EBR/GZR | 847 (5.3) | 825 (8.1) | 3 (0.1) | 0 | 6 (12.8) | 2 (0.4) | 11 (4.2) | |
| SOF/LDV±RBV | 4,856 (30.6) | 4,375 (42.7) | 132 (3.6) | 24 (2.1) | 25 (53.2) | 1 (100) | 219 (47.9) | 80 (30.7) |
| SOF/RBV | 2,785 (17.6) | 74 (0.7) | 2,593 (70.4) | 82 (7.1) | 2 (4.3) | 22 (4.8) | 12 (4.6) | |
| SOF/DCV±RBV | 382 (2.4) | 96 (0.9) | 149 (4.0) | 102 (8.9) | 0 | 16 (3.5) | 19 (7.3) | |
| GLE/PIB | 1,219 (7.7) | 530 (5.2) | 494 (13.4) | 68 (5.9) | 5 (10.6) | 70 (15.3) | 52 (19.9) | |
| SOF/VEL±RBV | 1,640 (10.4) | 381 (3.7) | 205 (5.6) | 851 (73.9) | 8 (17.0) | 122 (26.7) | 73 (28.0) | |
| Others | 160 (1.0) | 87 (0.9) | 30 (0.8) | 23 (2.0) | 1 (2.1) | 6 (1.3) | 13 (5.0) |
HCC, Hepatocellular carcinoma; HCV, Hepatitis C virus; HBV, Hepatitis B virus; HIV, Human immunodeficiency virus; DAA, Direct-acting antiviral; ALT, Alanine aminotransferase; AST, Aspartate aminotransferase; FIB-4, Fibrosis-4 index; APRI, AST to platelet ratio index; CTP, Child-Turcotte-Pugh; eGFR, Estimated glomerular filtration rate; SOF, Sofosbuvir; VEL, Velpatasvir; RBV, Ribavirin; DCV, Daclatasvir; ASV, Asunaprevir; LDV, Ledipasvir; PrOD, Paritaprevir/ritonavir, ombitasvir + dasabuvir; EBR, Elbasvir; GZR, Grazoprevir; GLE, Glecaprevir; PIB, Pibrentasvir.